Genprex (GNPX) Stock Price, News & Analysis

Company Overview

Genprex, Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

Key Stats

• Today's Range: $0.83 to $0.88
• 50-Day Range: $0.85 to $2.07
• 52-Week Range: $0.83 to $55.00
• Volume: 378,736 shs
• Average Volume: 1.29 million shs
• Market Capitalization: $8.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Genprex Stock Analysis - MarketRank™

Genprex scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Genprex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Genprex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Genprex has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.79% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 121.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genprex does not currently pay a dividend.

Dividend Growth

Genprex does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Genprex this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

5 people have added Genprex to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genprex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22.00 in company stock.

Percentage Held by Insiders

0.25% of the stock of Genprex is held by insiders.

Percentage Held by Institutions

14.05% of the stock of Genprex is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 5/11/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNPX
• CIK: 1595248
• Web: www.genprex.com
• Phone: (877) 774-4679
• Fax: N/A
• Employees: 20
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($26.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -464.05%
• Return on Assets: -275.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.84
• Quick Ratio: 3.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.42 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 10,420,000
• Free Float: 10,391,000
• Market Cap: $8.81 million
• Optionable: No Data
• Beta: -0.94